Condition: Glioma · Radiotherapy; Complications · Sponsor: Erasmus Medical Center
Rationale: Proton beam therapy has recently become available for the treatment of patients with WHO grade 2 and 3 IDH mutated (IDHmt) glioma in the Netherlands. The dose distributions associated with proton therapy have substantially reduced the volume of the normal brain irradiated with low and intermediate radiotherapy doses. Whether this impacts rates of progressive disease or safety issues and how this compares with a similar population treated with photon therapy is currently unknown. Objective: To investigate short term outcomes after proton and photon radiotherapy for grade 2 and 3 IDHmt glioma.
This description comes directly from the study's public registry record.
Steven HJ Nagtegaal, MD PhD · +31(0)107042249 · s.nagtegaal@erasmusmc.nl
Alejandra Mendez Romero, MD PhD · +31(0)107035829 · a.mendezromero@erasmusmc.nl
Always discuss trial participation with your own doctor first.
| Erasmus MC | Rotterdam, Netherlands | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06180434